Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Seminars in Oncology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2003.12.013PMID 14981579
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The proteasome as a target for cancer therapy.

  2003cited by this paper
• Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis

  2003cited by this paper
• Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Function of nuclear factor kappaB in pancreatic cancer metastasis.

  2003cited by this paper
• Clinical update: proteasome inhibitors in solid tumors.

  2003cited by this paper
• Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

  2003cited by this paper
• Function of Nuclear Factor κB in Pancreatic Cancer Metastasis

  2003cited by this paper
• P-245 The proteasome inhibitor, bortezomib, in combination with gemcitabine (gem) and carboplatin (carbon) in advanced non-small cell lung cancer (NSCLC): A phase I study

  2003cited by this paper
• Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

  2003cited by this paper
• The proteasome: structure, function, and role in the cell.

  2003cited by this paper
• Development of the proteasome inhibitor PS-341.

  2002cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

  2002cited by this paper
• Prognostic significance of p27KIP1 expression in resected non–small cell lung cancers: Analysis in combination with expressions of p16INK4A, pRB, and p53

  2002cited by this paper
• Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

  2002cited by this paper
• Clinical update of Ad-p53 gene therapy for lung cancer.

  2002cited by this paper
• Inhibition of NF-κB Activity Decreases the VEGF mRNA Expression in MDA-MB-231 Breast Cancer Cells

  2002cited by this paper
• Clinical significance of p21 expression in non-small-cell lung cancer.

  2002cited by this paper
• NF-kappaB as a therapeutic target in cancer.

  2002cited by this paper
• Nuclear factor-kappa B and cancer: its role in prevention and therapy.

  2002cited by this paper
• Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells.

  2002cited by this paper
• The role of ubiquitin-proteasome pathway in oncogenic signaling.

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer.

  2002cited by this paper
• NF-?B as a therapeutic target in cancer

  2002cited by this paper
• Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer

  2002cited by this paper
• The Role of the Ubiquitin-Proteasome Pathway in Oncogenic

  2002cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer.

  2001cited by this paper
• Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis.

  2001cited by this paper
• Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

  2001cited by this paper
• Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

  2000cited by this paper
• NF-κB Activation Is Related to the Resistance of Lung Cancer Cells to TNF-α-Induced Apoptosis

  2000cited by this paper
• NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis.

  2000cited by this paper
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  2000cited by this paper
• Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.

  2000cited by this paper
• Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Aberrant rel/nfkb genes and activity in human cancer

  1999cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper
• The proteasome inhibitor PS-341 in cancer therapy.

  1999cited by this paper
• Rel/NF-?B and I?B factors in oncogenesis

  1997cited by this paper
• p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.

  1997cited by this paper
• Rel/NF-kappa B and I kappa B factors in oncogenesis.

  1997cited by this paper
• In vivo ubiquitination and proteasome-mediated degradation of p53(1).

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• Protein degradation or regulation: Ub the judge.

  1996cited by this paper
• The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression.

  1995cited by this paper
• Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

  1995cited by this paper
• Transcriptional regulation of endothelial cell adhesion molecules: NF‐κB and cytokine‐inducible enhancers

  1995cited by this paper
• New insights into proteasome function: from archaebacteria to drug development.

  1995cited by this paper
• The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

  1994cited by this paper
• Regulation of proteasome expression in developing and transformed cells.

  1993cited by this paper
• The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

  1993cited by this paper
• Abnormally high expression of proteasomes in human leukemic cells.

  1990cited by this paper

• TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets.

  2021cites this paper
• Bax is involved in the anticancer activity of Velcade in colorectal cancer.

  2017cites this paper
• Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib

  2016cites this paper
• Role and inhibition of Src signaling in the progression of liver cancer

  2016cites this paper
• 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.

  2015cites this paper
• Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.

  2015cites this paper
• Ubiquitin-Proteasome Pathway and Prostate Cancer

  2013cites this paper
• treatment for refractory multiple myeloma Severe pulmonary complications in Japanese patients after bortezomib

  2012cites this paper
• Amino acid, peptide, and protein hydroperoxides and their decomposition products modify the activity of the 26S proteasome.

  2011cites this paper
• Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

  2011cites this paper
• Update 1 of: Proteases universally recognize beta strands in their active sites.

  2010cites this paper
• Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

  2010cites this paper
• Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells

  2010cites this paper
• Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity

  2008cites this paper
• Senescence Regulation in Cancer Therapy

  2008cites this paper
• Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.

  2007cites this paper
• Regulation of Mitochondria-dependent Apoptosis in Non-Small Cell Lung Cancer: Implications for Cancer Therapy

  2007cites this paper
• Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer

  2007cites this paper
• Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial

  2006cites this paper
• Severe pulmonary complications in African-American patient after bortezomib therapy.

  2006cites this paper
• Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

  2006cites this paper
• Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

  2006cites this paper
• Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

  2006cites this paper
• The potential of proteasome inhibition in the treatment of colon cancer

  2006cites this paper
• Small cell lung cancer.

  2006cites this paper
• Bortezomib as an antitumor agent.

  2006cites this paper
• Chemotherapy advances in small cell lung cancer.

  2006cites this paper
• Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors

  2005cites this paper
• Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).

  2005cites this paper
• [A new therapy with bortezomib, an oncologic medicinal product of the year 2004].

  2005cites this paper
• Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.

  2005cites this paper
• Proteases universally recognize beta strands in their active sites.

  2005cites this paper
• Targeting senescence pathways to reverse drug resistance in cancer.

  2005cites this paper
• The Ubiquitin-Proteasome Pathway

  2005cites this paper
• Une nouvelle thérapie ciblée avec le bortézomib, médicament oncologique de l’année 2004

  2005cites this paper
• Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo*

  2004cites this paper
• Targeted therapies for cancer 2004.

  2004cites this paper